Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) EBT: 2009-2024

Historic EBT for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$4.1 million.

  • Anika Therapeutics' EBT fell 788.00% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.3 million, marking a year-over-year decrease of 150.48%. This contributed to the annual value of -$4.1 million for FY2024, which is 229.21% down from last year.
  • Per Anika Therapeutics' latest filing, its EBT stood at -$4.1 million for FY2024, which was down 229.21% from $3.2 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' EBT registered a high of $5.0 million during FY2021, and its lowest value of -$28.6 million during FY2020.
  • Over the past 3 years, Anika Therapeutics' median EBT value was $3.2 million (recorded in 2023), while the average stood at $1.1 million.
  • Per our database at Business Quant, Anika Therapeutics' EBT spiked by 117.31% in 2021 and then slumped by 229.21% in 2024.
  • Yearly analysis of 5 years shows Anika Therapeutics' EBT stood at -$28.6 million in 2020, then surged by 117.31% to $5.0 million in 2021, then declined by 12.75% to $4.3 million in 2022, then dropped by 27.01% to $3.2 million in 2023, then tumbled by 229.21% to -$4.1 million in 2024.